It’s no secret to those following the news lately that the future of cannabis is looking bright following the recent U.S. elections.

On the heels of five U.S. states voting to legalize marijuana in some form last week, lawmakers in Texas are getting a head start introducing a number of cannabis-related bills for next year, including one that would legalize it for adult use.

Less than a week after an Election Day in which voters in five states approved ballot measures to legalize marijuana in some form, a top leader in the U.S. House of Representatives announced that the body will hold a floor vote on a bill to end federal cannabis prohibition next month.

Three new psychedelic stocks are trading publicly. One commenced trading last week, two more are coming this week.

Oregon has legalized the medicinal use of psilocybin. Here is why that’s big news for the psychedelic drug industry.

The narrow loss of 2016 has been erased.

Cybin Corp has completed its RTO and received approval to commence trading on the NEO Exchange (symbol “CYBN”) and expects to begin trading on or about November 10th.

A study of 27 people found that psilocybin therapy was more effective than traditional antidepressant medications, “producing large, rapid, and sustained antidepressant effects in patients with major depressive disorder.”

Entheon Biomedical has announced that it expects to commence public trading on or about November 12th, symbol “ENBI”.

South Dakota voters have approved two ballot initiatives to legalize marijuana for recreational and medical purposes, according to projections from the Associated Press.